The Role of Radiotherapy in StageI, II Intermediate Grade Non-Hodgkin's Lymphoma.
- Author:
Hyong Geun YUN
1
;
Il Han KIM
;
Heung Tae KIM
;
Yong Chan AHN
;
Jae Sung KIM
;
Sung Whan HA
;
Charn Il PARK
Author Information
1. Department of Therapeutic Radiology, College of Medicine, Seoul National University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Radiotherapy;
Non-Hodgkin's Lymphoma;
Intermediate grade;
StageI, II
- MeSH:
Disease-Free Survival;
Drug Therapy;
Humans;
Lymphoma, Non-Hodgkin*;
Prognosis;
Radiotherapy*;
Survival Rate
- From:Journal of the Korean Society for Therapeutic Radiology
1991;9(1):103-110
- CountryRepublic of Korea
- Language:English
-
Abstract:
Radiotherapy result of 162 patients with stage I, II Intermediate Grade Non-Hodgkin's lymphoma was analyzed to clarify the role and limit of radiotherapy. Of 68 initial failures, 38.2% stageI was 30.0% and 70.0%, respectively with involved field treatment and was 43.8% and 56.2% with extended field treatment, respectively; in stageII, was 16.7% and 83.3%, 41.7% and 58.3% and 40.4% for patients with stage I and II, respectively. The survival was significantly different by stage. Bulky tumors (> or =10 cm) and B symptoms didn't influence prognosis significantly. The 5 year disease free survival with extended or wide field was better than that with involved field especially in stage I. Overall survival rates for all patients, patients with stageI, and II disease were 57.7%, 65.3% and 52.2%, respectively, after survival gain of the salvage chemotherapy was combined. But the overall survival of stageI disease was not better than that of stageII disease. Thus, extended field was required to achieve better disease free survival and relapsed cases might gain with chemotherapy.
